|Project Title||Quantifying Prevalence and Mortality Associated with Neonatal Enteroviral Sepsis (NES) Using Inpatient Data in FDA’s Sentinel System|
Tuesday, November 27, 2018
Neonatal enteroviral sepsis (NES) is a severe enterovirus (EV) infection in the neonate that may manifest with serious complications such as hepatic necrosis, coagulopathy, and myocarditis. Currently no U.S. Food and Drug Administration (FDA) approved drug product exists for the treatment of NES, although reports indicate intravenous immune globulin (IVIG) is sometimes administered. FDA required observational data on NES prevalence and mortality rates to inform the design of future clinical trials to evaluate investigational new drugs for NES treatment. The objective of this project is to describe NES prevalence and mortality rates among hospitalized neonates in the Sentinel System.
neonatal enteroviral sepsis (NES)
|Population / Cohort||
All children 60 days of age and younger
July 1, 2012 - March 31, 2016
Sentinel Distributed Database (SDD)